Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
BACKGROUND
BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries.


METHODS
We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST.


RESULTS
A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%).


CONCLUSIONS
BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.
Department of Dermatovenereology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
Martina
M
Kojanova
Department of Dermatovenereology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
Jorga
J
Fialova
Department of Dermatovenereology, Charles University, Faculty of Medicine and University Hospital, Pilsen, Czech Republic.
Petra
P
Cetkovska
Department of Dermatovenereology, Charles University, Third Faculty of Medicine and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
Spyridon
S
Gkalpakiotis
VALUE OUTCOMES, Prague, Czech Republic.
Jitka
J
Jircikova
VALUE OUTCOMES, Prague, Czech Republic.
Tomas
T
Dolezal
Department of Dermatovenereology, Charles University, Third Faculty of Medicine and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
Petr
P
Arenberger
D017255:Acitretin / Q000627:therapeutic use; D000328:Adult; D001688:Biological Products / Q000627:therapeutic use*; D015992:Body Mass Index; D015897:Comorbidity; D003327:Coronary Disease / Q000453:epidemiology; D016572:Cyclosporine / Q000627:therapeutic use; D018153:Czech Republic / Q000453:epidemiology; D003879:Dermatologic Agents / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D007641:Keratolytic Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology*; D010789:Phototherapy; D015995:Prevalence; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology* / Q000628:therapy; D011788:Quality of Life; D012042:Registries; D019233:Retreatment; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index
D001688:Biological Products; D003879:Dermatologic Agents; D007641:Keratolytic Agents; D016572:Cyclosporine; D017255:Acitretin; D008727:Methotrexate